Biologics Development| Amgen Biosimilars

Biologics Development

Our mission is our patients

As a world leader and innovator in biologics for patients with life-threatening and chronic diseases, Amgen is proud to produce biosimilar medicines in pursuit of its mission: to serve patients.

Amgen’s core focus is to discover, develop, and deliver innovative medicines for patients with serious illnesses. We are inspired every day to develop robust and differentiated therapeutics, from originator biologics to biosimilars.

Networks that run wide and deep

Amgen’s long-standing commitment to innovation in biotechnology has led to the launch of 18 widely used biologic therapies and a portfolio of 10 biosimilar medicines, including potential treatments for cancer and chronic inflammatory diseases.*

This long-standing commitment means that you can trust us to be a true partner and innovator in biologic medicines, including biosimilars.

*As of August 8, 2019.

Amgen is committed to developing medicines across 6 therapeutic areas

cell group cell group